Use Nektar Therapeutics story together with your assets to protect against small markets fluctuations as well as to check it against diversification policy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price decline. The story delta to the next closing price was 9.90% . The story delta to the current price is 44.74% .
Do you like to follow the buying trends of smart money investors? These investors include institutional investors such as hedge fund managers, and because of their experience and access to sophisticated research, their reported stock purchases are very ...
Sacramento Bee - Apr 10, 2012
By Nektar Therapeutics SAN FRANCISCO, April 10, 2012 -- /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 pm to 5:00 ...
pharmabiz.com - Apr 4, 2012
Nektar Therapeutics, a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has dosed first subject in a phase I clinical study to evaluate the pharmacokinetics and ...
Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a ... - PR Newswire (press release)
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
